Sharemaestro Newsreel

Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $26.7, Implies 22% Upside

Amylyx Pharmaceuticals, Inc. (AMLX) has seen its average 12-month price target raised from $25.56 to $26.7 by 10 analysts, suggesting a 22% potential upside from its August 5th closing price. The consensus rating remains a "Buy" from 11 analysts, with 10 recommending "Buy" and …

Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary

Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased …

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality

Amneal Pharmaceuticals reported healthy earnings, but the stock price remained stable. The company's profit was impacted by US$81m in unusual expenses, which are likely one-off events, suggesting higher future profits. The article highlights that these unusual items might cause Amneal Pharmaceuticals' statutory profit to …

Stronger EPS, Ralinepag Progress, and Buybacks Might Change The Case For Investing In United Therapeutics (UTHR)

ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ:AQST) securities. The investigation focuses on whether Aquestive officers and/or directors engaged in corporate wrongdoing, particularly for investors who purchased shares before June 16, 2025, and still …

Form 8K Canopy Growth Corp For: 7 August By Investing.com

This article announces the filing of a

Canopy Growth (CGC) Tops Q1 EPS by 3c

Canopy Growth (CGC) reported better-than-expected Q1 earnings, with an EPS of Cdn$0.03, surpassing analyst estimates by Cdn$0.03. The company also exceeded revenue expectations, bringing in Cdn$81.2 million against a consensus estimate of Cdn$58.89 million.

Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $266.0M, vs. FactSet Est of $260.1M

ANI Pharmaceuticals, Inc. (ANIP) reported its Q2 revenue of $266.0 million, surpassing the FactSet estimate of $260.1 million. The company also announced Q2 adjusted EPS of $2.21 per share, exceeding the FactSet estimate of $2.04. Furthermore, ANI Pharmaceuticals expects 2026 net revenue in the …

Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $2.21 per Share, vs. FactSet Est of $2.04

ANI Pharmaceuticals, Inc. (ANIP) reported Q2 adjusted EPS of $2.21 per share, surpassing FactSet's estimate of $2.04. The company's adjusted earnings and revenue both rose in Q2. Additionally, ANI Pharmaceuticals expects 2026 net revenue to range between $1.08 billion and $1.14 billion and adjusted …

Amundi Increases Stake in Alkermes plc $ALKS

Amundi significantly increased its stake in Alkermes plc (NASDAQ:ALKS) during the first quarter, nearly doubling its holdings to 64,710 shares valued at approximately $2.29 million. Institutional investors now own 95.21% of the company's stock, which trades between a 52-week low of $25.17 and a …

ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook

IM Cannabis Corp (IMCC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Canopy Growth (NASDAQ: CGC) trims loss, outlines Acreage debt risk

Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-08-07

Collegium Pharmaceutical, Inc. (COLL) released its Q2 2026 earnings call presentation. The company reported an EPS of $1.92, beating estimates by $0.16, and revenue of $199.88M, which missed estimates by $1.07M but represented a 6.32% year-over-year increase. This presentation provides details on their financial …

Alpha Teknova (TKNO) Stock Climbs On Record Revenue As Breakeven Draws Closer

Alpha Teknova (TKNO) stock climbed 16.4% on record Q2 revenue of over US$12 million and a narrowed net loss, signaling positive market sentiment. The company is making progress towards EBITDA breakeven with steady growth in Lab Essentials and Clinical Solutions, improved gross margins, and …

BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for BIOAGE Labs Inc (BIOA), highlighting an earnings forecast score of 8.44 and an average price target of $12.00. Based on ratings from 9 analysts, the stock is predominantly recommended as a "Buy." Key financial expectations include an …

Earnings call transcript: Amphastar rises after q2 2026 revenue beat By Investing.com

Earnings Flash (TRLV) Trulieve Cannabis Corp. Reports Q2 Revenue $271.0M, vs. FactSet Est of $268.5M

Trulieve Reports Second Quarter 2026 Results - Investors

Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Collegium Pharmaceutical Inc (COLL), detailing its current price momentum score, support and resistance levels, and indicator readings. It also covers moving average data and offers a technical summary, suggesting the stock is currently suitable for range-bound swing …

BIOAGE Labs Inc (BIOA) Stock News Today

Why Did IXHL Stock Tank Over 32% Today?

Incannex Healthcare Inc. (IXHL) announced a 1-for-30 reverse stock split, which became legally effective on February 26, 2026. This move is intended to help the company comply with Nasdaq’s minimum bid price requirements. Following the announcement, IXHL stock declined over 32%, despite the company …

Cronos Group Inc. (CRON) Stock Analysis: Navigating a 40% Revenue Growth with Investor Ratings in Focus

Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026

Canopy Growth Corporation (TSX: WEED, Nasdaq: CGC) announced it will release its financial results for the first quarter fiscal year 2027, which ended June 30, 2026, before financial markets open on August 7, 2026. The company will host an audio webcast with CEO Luc …

Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter

Viatris reported a strong second quarter with 5% revenue growth and 11% adjusted earnings per share growth, both surpassing FactSet consensus estimates. The company also raised its EPS guidance by 5% at the midpoint, despite shares trading down 3% post-announcement. This performance highlights solid …

Arrowstreet Capital Limited Partnership Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Arrowstreet Capital Limited Partnership significantly reduced its stake in Teva Pharmaceutical Industries Ltd. by 72.9% in the first quarter, selling 104,530 shares and retaining 38,900 shares worth $1.17 million. Despite this reduction and an insider sale, institutional investors still hold a majority stake of …

How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors

BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of US$218.25 million and a net income of US$78.40 million, while raising its full-year 2026 revenue guidance to US$690 million to US$715 million. This positive short-term outlook, driven by ORLADEYO sales, contrasts with a six-month net loss …

BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Earnings Flash (WEED.TO) Canopy Growth Corporation Reports Q1 Revenue C$81.2M, vs. FactSet Est of C$82.7M

Canopy Growth Corporation (WEED.TO) reported its Q1 revenue as C$81.2 million, falling short of the FactSet estimate of C$82.7 million. The cannabis company specializes in a diverse range of cannabis and related products for both adult-use and medical purposes, with brands including Tweed, DOJA, …

Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday

Cardiol Therapeutics (CRDL) is anticipated to release its Q2 2026 earnings on Thursday, August 13th, with analysts forecasting a loss of $0.09 per share. The company's previous quarter reported a loss of $0.07 per share, meeting estimates. CRDL shares opened at $1.34, and analysts …

Cronos Group reports Q2 2026: Net revenue $53.0M, gross profit $28.5M, adjusted EBITDA $13.1M

Cronos Group announced strong organic results for Q2 2026, reporting net revenue of $53.0 million, gross profit of $28.5 million, and adjusted EBITDA of $13.1 million. The company achieved a net income of $35.7 million with EPS of $0.09 and repurchased 12.3 million shares …

Breathe Right and LaCorium Acquisitions Raise Prestige Consumer's 2027 Outlook

Prestige Consumer Healthcare reported strong Q1 fiscal 2027 results with revenue up 6.5% to $265.7 million and adjusted diluted EPS rising to $0.98. The company's recent acquisitions of Breathe Right and LaCorium Health significantly contributed to these results and led to a raised fiscal …

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum